Complement component 3 negatively regulates antibody response by modulation of red blood cell antigen

Frontiers in Immunology

Volumn 9, Issue JUN, 2018, Pages

  Mener, Amanda ^a   Arthur, Connie M ^a   Patel, Seema R ^a   Liu, Jingchun ^b   Hendrickson, Jeanne E ^b   Stowell, Sean R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alloimmunization; Antigen modulation; Complement component 3; Humoral immunity; Red blood cells

Indexed keywords

ANTIGEN; COMPLEMENT COMPONENT C3; HOD ANTIGEN; KEL ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; IMMUNE RESPONSE; MOUSE; NONHUMAN; WESTERN BLOTTING; WILD TYPE;

EID: 85048327394     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00676     Document Type: Article

References (116)

1. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med (1990) 322:1617-21. doi:10.1056/NEJM199006073222301
2. Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, et al. Transfusion and alloimmunization in sickle cell disease. The cooperative study of sickle cell disease. Blood (1990) 76:1431-7
3. Hillyer CD, Shaz BH, Winkler AM, Reid M. Integrating molecular technologies for red blood cell typing and compatibility testing into blood centers and transfusion services. Transfus Med Rev (2008) 22:117-32. doi:10.1016/j.tmrv.2007.12.002
4. Nickel RS, Hendrickson JE, Fasano RM, Meyer EK, Winkler AM, Yee MM, et al. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion (2015) 56(1):107-14. doi:10.1111/trf.13379
5. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood (2008) 120:528-37. doi:10.1182/blood-2011-11-327361
6. Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion (2002) 42:684-90. doi:10.1046/j.1537-2995.2002.00126.x
7. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion (2002) 42:37-43. doi:10.1046/j.1537-2995.2002.00007.x
8. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood (2013) 122:1062-71. doi:10.1182/blood-2013-03-490623
9. Gilliland BC, Baxter E, Evans RS. Red-cell antibodies in acquired hemolytic anemia with negative antiglobulin serum tests. N Engl J Med (1971) 285:252-6. doi:10.1056/NEJM197107292850503
10. Coombs RR, Mourant AE, Race R. A new test for the detection of weak and 'incomplete' Rh agglutinins. Br J Exp Pathol (1945) 26:255
11. Talano J-AM, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics (2003) 111:e661-5. doi:10.1542/peds.111.6.e661
12. Habibi A, Mekontso-Dessap A, Guillaud C, Michel M, Razazi K, Khellaf M, et al. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes. Am J Hematol (2016) 91:989-94. doi:10.1002/ajh.24460
13. Da Costa XJ, Brockman MA, Alicot E, Ma M, Fischer MB, Zhou X, et al. Humoral response to herpes simplex virus is complement-dependent. Proc Natl Acad Sci U S A (1999) 96:12708-12. doi:10.1073/pnas.96.22.12708
14. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol (2004) 5:981-6. doi:10.1038/ni1113
15. Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity (2012) 37:199-207. doi:10.1016/j.immuni.2012.08.002
16. Ahearn JM, Fischer MB, Croix D, Goerg S, Ma M, Xia J, et al. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity (1996) 4:251-62. doi:10.1016/S1074-7613(00)80433-1
17. Fischer MB, Goerg S, Shen L, Prodeus AP, Goodnow CC, Kelsoe G, et al. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science (1998) 280(5363):582-5. doi:10.1126/science.280.5363.582
18. Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A (1995) 92:11490-4. doi:10.1073/pnas.92.25.11490
19. Polley MJ, Mollison P. The role of complement in the detection of blood group antibodies: special reference to the antiglobulin test. Transfusion (1961) 1:9-22. doi:10.1111/j.1537-2995.1961.tb00006.x
20. Harboe M, Müller-Eberhard H, Fudenberg H, Polley MJ, Mollison P. Identification of the components of complement participating in the antiglobulin reaction. Immunology (1963) 6:412
21. Mollison PL, Crome P, Hughes-Jones NC, Rochna E. Rate of removal from the circulation of red cells sensitized with different amounts of antibody. Br J Haematol (1965) 11:461-70. doi:10.1111/j.1365-2141.1965.tb06609.x
22. Mollison P. The role of complement in antibody-mediated red-cell destruction. Br J Haematol (1970) 18:249-56. doi:10.1111/j.1365-2141.1970.tb01440.x
23. Mollison PL, Newlands M. Unusual delayed haemolytic transfusion reaction characterised by slow destruction of red cells. Vox Sang (1976) 31:54-7. doi:10.1159/000467284
24. Stowell SR, Winkler AM, Maier CL, Arthur CM, Smith NH, Girard-Pierce KR, et al. Initiation and regulation of complement during hemolytic transfusion reactions. Clin Dev Immunol (2012) 2012:307093. doi:10.1155/2012/307093
25. Fischer MB, Ma M, Goerg S, Zhou X, Xia J, Finco O, et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol (1996) 157:549-56
26. Pozdnyakova O, Guttormsen H-K, Lalani FN, Carroll MC, Kasper DL. Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3-and complement receptor 2-deficient mice. J Immunol (2003) 170:84-90. doi:10.4049/jimmunol.170.1.84
27. Fan X, Lang H, Zhou X, Zhang L, Yin R, Maciejko J, et al. Induction of human blood group a antigen expression on mouse cells, using lentiviral gene transduction. Hum Gene Ther (2010) 21:877-90. doi:10.1089/hum.2008.089
28. Larkin JM, Porter CD. Mice are unsuitable for modelling ABO discordance despite strain-specific A cross-reactive natural IgM. Br J Haematol (2005) 130:310-7. doi:10.1111/j.1365-2141.2005.05609.x
29. Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest (1972) 51:575-82. doi:10.1172/JCI106846
30. Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest (1972) 51:583-9. doi:10.1172/JCI106847
31. Spiegelberg HL, Miescher PA, Benacerraf B. Studies on the role of complement in the immune clearance of Escherichia coli and rat erythrocytes by the reticuloendothelial system in mice. J Immunol (1963) 90:751-9
32. Stowell SR, Henry KL, Smith NH, Hudson KE, Halverson GR, Park JC, et al. Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model. Blood (2013) 122:1494-504. doi:10.1182/blood-2013-03-488874
33. Stowell SR, Arthur CM, Girard-Pierce KR, Sullivan HC, Santhanakrishnan M, Natarajan P, et al. Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model. Haematologica (2015) 100:e394-7. doi:10.3324/haematol.2015.128603
34. Girard-Pierce KR, Stowell SR, Smith NH, Arthur CM, Sullivan HC, Hendrickson JE, et al. A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation. Blood (2013) 122:1793-801. doi:10.1182/blood-2013-06-508952
35. Smith NH, Henry KL, Cadwell CM, Bennett A, Hendrickson JE, Frame T, et al. Generation of transgenic mice with antithetical KEL1 and KEL2 human blood group antigens on red blood cells. Transfusion (2012) 52:2620-30. doi:10.1111/j.1537-2995.2012.03641.x
36. Desmarets M, Cadwell CM, Peterson KR, Neades R, Zimring JC. Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model. Blood (2009) 114:2315-22. doi:10.1182/blood-2009-04-214387
37. Stowell SR, Liepkalns JS, Hendrickson JE, Girard-Pierce KR, Smith NH, Arthur CM, et al. Antigen modulation confers protection to red blood cells from antibody through Fcgamma receptor ligation. J Immunol (2013) 191:5013-25. doi:10.4049/jimmunol.1300885
38. Zimring JC, Hair GA, Chadwick TE, Deshpande SS, Anderson KM, Hillyer CD, et al. Nonhemolytic antibody-induced loss of erythrocyte surface antigen. Blood (2005) 106:1105-12. doi:10.1182/blood-2005-03-1040
39. Sullivan HC, Gerner-Smidt C, Nooka AK, Arthur CM, Thompson L, Mener A, et al. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood (2017) 129:3033-7. doi:10.1182/blood-2016-11-749432
40. Arthur CM, Patel SR, Sullivan HC, Winkler AM, Tormey CA, Hendrickson JE, et al. CD8+ T cells mediate antibody-independent platelet clearance in mice. Blood (2016) 127:1823-7. doi:10.1182/blood-2015-10-673426
41. Arthur CM, Patel SR, Smith NH, Bennett A, Kamili NA, Mener A, et al. Antigen density dictates immune responsiveness following red blood cell transfusion. J Immunol (2017) 198:2671-80. doi:10.4049/jimmunol.1601736
42. Patel SR, Cadwell CM, Medford A, Zimring JC. Transfusion of minor histocompatibility antigen-mismatched platelets induces rejection of bone marrow transplants in mice. J Clin Invest (2009) 119:2787. doi:10.1172/JCI39590
43. Stowell SR, Girard-Pierce KR, Smith NH, Henry KL, Arthur CM, Zimring JC, et al. Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies. Transfusion (2014) 54:179-89. doi:10.1111/trf.12217
44. Liu J, Santhanakrishnan M, Natarajan P, Gibb DR, Eisenbarth SC, Tormey CA, et al. Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice. Blood (2016) 128:3159-68. doi:10.1182/blood-2016-06-724732
45. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 146:257-70. doi:10.1084/jem.146.1.257
46. Pangburn MK, Muller-Eberhard HJ. Kinetic and thermodynamic analysis of the control of C3b by the complement regulatory proteins factors H and I. Biochemistry (1983) 22:178-85. doi:10.1021/bi00270a026
47. Ross GD, Lambris JD, Cain JA, Newman SL. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol (1982) 129:2051-60
48. Ross GD, Newman SL, Lambris JD, Devery-Pocius JE, Cain JA, Lachmann PJ. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin. J Exp Med (1983) 158:334-52. doi:10.1084/jem.158.2.334
49. Carroll MC. The complement system in B cell regulation. Mol Immunol (2004) 41:141-6. doi:10.1016/j.molimm.2004.03.017
50. Ochsenbein AF, Pinschewer DD, Odermatt B, Carroll MC, Hengartner H, Zinkernagel RM. Protective T cell-independent antiviral antibody responses are dependent on complement. J Exp Med (1999) 190:1165-74. doi:10.1084/jem.190.8.1165
51. Verschoor A, Brockman MA, Gadjeva M, Knipe DM, Carroll MC. Myeloid C3 determines induction of humoral responses to peripheral herpes simplex virus infection. J Immunol (2003) 171:5363-71. doi:10.4049/jimmunol.171.10.5363
52. Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med (2002) 8:373-8. doi:10.1038/nm0402-373
53. Yalcindag A, He R, Laouini D, Alenius H, Carroll M, Oettgen HC, et al. The complement component C3 plays a critical role in both Th1 and Th2 responses to antigen. J Allergy Clin Immunol (2006) 117:1455-61. doi:10.1016/j.jaci.2006.01.048
54. Moller G. Isoantibody-induced cellular resistance to immune haemolysis in vivo and in vitro. Nature (1964) 202:357-9. doi:10.1038/202357a0
55. Ruddy S, Austen KF. C3b inactivator of man II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 107:742-50
56. Lachmann PJ, Pangburn MK, Oldroyd RG. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 156:205-16. doi:10.1084/jem.156.1.205
57. Muller-Eberhard HJ. Molecular organization and function of the complement system. Annu Rev Biochem (1988) 57:321-47. doi:10.1146/annurev.bi.57.070188.001541
58. Zimring JC, Cadwell CM, Chadwick TE, Spitalnik SL, Schirmer DA, Wu T, et al. Nonhemolytic antigen loss from red blood cells requires cooperative binding of multiple antibodies recognizing different epitopes. Blood (2007) 110:2201-8. doi:10.1182/blood-2007-04-083097
59. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 80:5430-4. doi:10.1073/pnas.80.17.5430
60. Walport MJ. Complement. Second of two parts. N Engl J Med (2001) 344:1140-4. doi:10.1056/NEJM200104123441506
61. Walport MJ. Complement. First of two parts. N Engl J Med (2001) 344:1058-66. doi:10.1056/NEJM200104053441406
62. Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol (2013) 735:155-72. doi:10.1007/978-1-4614-4118-2_10
63. Hillmen P. The role of complement inhibition in PNH. Hematology Am Soc Hematol Educ Program (2008) 2008(1):116-23. doi:10.1182/asheducation-2008.1.116
64. Mastellos DC, Ricklin D, Yancopoulou D, Risitano A, Lambris JD. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev Hematol (2014) 7:583-98. doi:10.1586/17474086.2014.953926
65. Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell (2006) 124:915-27. doi:10.1016/j.cell.2005.12.039
66. Graham IL, Anderson DC, Holers VM, Brown EJ. Complement receptor 3 (CR3, Mac-1, integrin alpha M beta 2, CD11b/CD18) is required for tyrosine phosphorylation of paxillin in adherent and nonadherent neutrophils. J Cell Biol (1994) 127:1139-47. doi:10.1083/jcb.127.4.1139
67. Taborda CP, Casadevall A. CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity (2002) 16:791-802. doi:10.1016/S1074-7613(02)00328-X
68. Brown EJ. Complement receptors and phagocytosis. Curr Opin Immunol (1991) 3:76-82. doi:10.1016/0952-7915(91)90081-B
69. Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med (2009) 360:542-4. doi:10.1056/NEJMc0808527
70. Ferreira VP, Pangburn MK. Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. Blood (2007) 110:2190-2. doi:10.1182/blood-2007-04-083170
71. Smith GN, Mollison PL. Suppression of primary immunization to the rabbit red cell alloantigen HgA by passively administered anti-HgA. Immunology (1974) 26:885-92
72. Bernardo L, Amash A, Marjoram D, Lazarus AH. Antibody-mediated immune suppression is improved when blends of anti-RBC monoclonal antibodies are used in mice. Blood (2016) 128:1076-80. doi:10.1182/blood-2016-01-692178
73. Kumpel BM, Goodrick MJ, Pamphilon DH, Fraser ID, Poole GD, Morse C, et al. Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D-volunteers. Blood (1995) 86:1701-9
74. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med (2002) 195:335-41. doi:10.1084/jem.20010934
75. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 393:480-3. doi:10.1038/31002
76. Nie Y, Waite J, Brewer F, Sunshine MJ, Littman DR, Zou YR. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med (2004) 200:1145-56. doi:10.1084/jem.20041185
77. Pereira JP, Kelly LM, Cyster JG. Finding the right niche: B-cell migration in the early phases of T-dependent antibody responses. Int Immunol (2010) 22:413-9. doi:10.1093/intimm/dxq047
78. Sullivan HC, Arthur CM, Thompson L, Patel SR, Hendrickson JE, Lazarus AH, et al. Anti-RhD reduces levels of detectable RhD antigen following anti-RhD infusion. Transfusion (2018) 58(2):542-4. doi:10.1111/trf.14452
79. Swanson SM, Dombrink-Kurtzman MA, Voss EW Jr. C1q binding by a high affinity anti-fluorescein murine monoclonal IgM antibody and monomeric subunits. Mol Immunol (1988) 25:545-54. doi:10.1016/0161-5890(88)90076-4
80. Lucisano Valim YM, Lachmann PJ. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 84:1-8. doi:10.1111/j.1365-2249.1991.tb08115.x
81. Lee S, Russo D, Redman C. Functional and structural aspects of the Kell blood group system. Transfus Med Rev (2000) 14:93-103. doi:10.1016/S0887-7963(00)80001-2
82. Hod E, Arinsburg S, Francis R, Hendrickson J, Zimring J, Spitalnik S. Use of mouse models to study the mechanisms and consequences of RBC clearance. Vox Sang (2010) 99:99-111. doi:10.1111/j.1423-0410.2010.01327.x
83. Nonaka M. Evolution of the complement system. Curr Opin Immunol (2001) 13:69-73. doi:10.1016/S0952-7915(00)00184-9
84. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol (1998) 16:545-68. doi:10.1146/annurev.immunol.16.1.545
85. Groom A, Schmidt E, MacDonald I. Microcirculatory pathways and blood flow in spleen: new insights from washout kinetics, corrosion casts, and quantitative intravital videomicroscopy. Scanning Microsc (1991) 5:159-73; discussion 173-4
86. Drenckhahn D, Wagner J. Stress fibers in the splenic sinus endothelium in situ: molecular structure, relationship to the extracellular matrix, and contractility. J Cell Biol (1986) 102:1738-47. doi:10.1083/jcb.102.5.1738
87. Cornacoff J, Hebert LA, Smead W, VanAman M, Birmingham DJ, Waxman F. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest (1983) 71:236. doi:10.1172/JCI110764
88. He JQ, Wiesmann C, van Lookeren Campagne M. A role of macrophage complement receptor CRIg in immune clearance and inflammation. Mol Immunol (2008) 45:4041-7. doi:10.1016/j.molimm.2008.07.011
89. Aichele P, Zinke J, Grode L, Schwendener RA, Kaufmann SHE, Seiler P. Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses. J Immunol (2003) 171:1148-55. doi:10.4049/jimmunol.171.3.1148
90. Martin F, Oliver AM, Kearney JF. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity (2001) 14:617-29. doi:10.1016/S1074-7613(01)00129-7
91. Balázs M, Martin F, Zhou T, Kearney JF. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity (2002) 17:341-52. doi:10.1016/S1074-7613(02)00389-8
92. Lambris JD. The multifunctional role of C3, the third component of complement. Immunol Today (1988) 9:387-93. doi:10.1016/0167-5699(88)91240-6
93. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol (2006) 118:127-36. doi:10.1016/j.clim.2005.10.014
94. Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med (1980) 152:20-30. doi:10.1084/jem.152.1.20
95. Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci U S A (1980) 76:5867-71. doi:10.1073/pnas.76.11.5867
96. Johnson AM, Alper CA, Rosen FS, Craig JM. C1 inhibitor: evidence for decreased hepatic synthesis in hereditary angioneurotic edema. Science (1971) 173:553-4. doi:10.1126/science.173.3996.553
97. Pangburn MK, Muller-Eberhard HJ. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A (1978) 75:2416-20. doi:10.1073/pnas.75.5.2416
98. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 129:184-9
99. Shemin D, Rittenberg D. The life span of the human red blood cell. J Biol Chem (1946) 166:627-36
100. Bordet J. Studies in Immunity. New York: John Wiley and Sons (1909)
101. Kazatchkine MD, Fearon DT, Silbert JE, Austen KF. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med (1979) 150:1202-15. doi:10.1084/jem.150.5.1202
102. Brinc D, Le-Tien H, Crow AR, Siragam V, Freedman J, Lazarus AH. Immunoglobulin G-mediated regulation of the murine immune response to transfused red blood cells occurs in the absence of active immune suppression: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the fetus and newborn? Immunology (2008) 124(1):141-6. doi:10.1111/j.1365-2567.2008.02807.x
103. Wang X, Cho B, Suzuki K, Xu Y, Green JA, An J, et al. Follicular dendritic cells help establish follicle identity and promote B cell retention in germinal centers. J Exp Med (2011) 208:2497-510. doi:10.1084/jem.20111449
104. Yi T, Li J, Chen H, Wu J, An J, Xu Y, et al. Splenic dendritic cells survey red blood cells for missing self-CD47 to trigger adaptive immune responses. Immunity (2015) 43:764-75. doi:10.1016/j.immuni.2015.08.021
105. Daggett CW, Yeatman M, Lodge AJ, Chen EP, Van Trigt P, Byrne GW, et al. Swine lungs expressing human complement-regulatory proteins are protected against acute pulmonary dysfunction in a human plasma perfusion model. J Thorac Cardiovasc Surg (1997) 113:390-8. doi:10.1016/S0022-5223(97)70337-4
106. Begum NA, Murakami Y, Mikata S, Matsumoto M, Hatanaka M, Nagasawa S, et al. Molecular remodelling of human CD46 for xenotransplantation: designing a potent complement regulator without measles virus receptor activity. Immunology (2000) 100:131-9. doi:10.1046/j.1365-2567.2000.00999.x
107. Hashemi-Najafabadi S, Vasheghani-Farahani E, Shojaosadati SA, Rasaee MJ, Armstrong JK, Moin M, et al. A method to optimize PEG-coating of red blood cells. Bioconjug Chem (2006) 17:1288-93. doi:10.1021/bc060057w
108. Murad KL, Mahany KL, Brugnara C, Kuypers FA, Eaton JW, Scott MD. Structural and functional consequences of antigenic modulation of red blood cells with methoxypoly(ethylene glycol). Blood (1999) 93:2121-7
109. Tormey CA, Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood (2009) 114:4279-82. doi:10.1182/blood-2009-06-227793
110. Salama A, Mueller-Eckhardt C. Binding of fluid phase C3b to nonsensitized bystander human red cells. A model for in vivo effects of complement activation on blood cells. Transfusion (1985) 25:528-34. doi:10.1046/j.1537-2995.1985.25686071424.x
111. Salama A, Mueller-Eckhardt C. Delayed hemolytic transfusion reactions. Evidence for complement activation involving allogeneic and autologous red cells. Transfusion (1984) 24:188-93. doi:10.1046/j.1537-2995.1984.24384225018.x
112. Fasano RM, Booth GS, Miles M, Du L, Koyama T, Meier ER, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol (2015) 168:291-300. doi:10.1111/bjh.13123
113. Schonewille H, Doxiadis II, Levering WH, Roelen DL, Claas FH, Brand A. HLA-DRB1 associations in individuals with single and multiple clinically relevant red blood cell antibodies. Transfusion (2014) 54:1971-80. doi:10.1111/trf.12624
114. Chaplin H, Nasongkla M, Monroe MC. Quantitation of red blood cell-bound C3d in normal subjects and random hospitalized patients. Br J Haematol (1981) 48:69-78. doi:10.1111/j.1365-2141.1981.00069.x
115. Freedman J, Barefoot C. Red blood cell-bound C3d in normal subjects and in random hospital patients. Transfusion (1982) 22:511-4. doi:10.1046/j.1537-2995.1982.22683068616.x
116. Telen MJ, Afenyi-Annan A, Garrett ME, Combs MR, Orringer EP, Ashley-Koch AE. Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. Transfusion (2015) 55:1378-87. doi:10.1111/trf.12940